KR102355798B1 - Composition for Treating or Relieving Comprising Complex Plant Extracts - Google Patents

Abstract

The present invention relates to a composition comprising at least two kinds of plant extracts from among complex plant extracts including motherwort ( Leonurus japonicas Houtt.) extract, Eclipta porstrata Linne extract, and Pueraria labata Ohwi extract. The composition of the present invention may be used as a drug for treating or preventing female menopausal symptoms and/or as a health functional food for alleviating female menopausal symptoms.

Description

Composition for Treating or Relieving Comprising Complex Plant Extracts for Treating or Alleviating Female Menopause Symptoms Containing Complex Plant Extracts

The present invention relates to a pharmaceutical composition and/or a food composition, and more particularly, to a composition for treating or alleviating female menopausal symptoms comprising two or more complex plant extracts as an active ingredient, and a health functional food comprising the same.

It is called 'menopause' because it is often said that a woman starts a new life around the age of 50, and it refers to the time when menstruation disappears and menstrual function changes. Menopause necessarily comes as a concept that can be applied to both men and women, and is a stage of aging when significant physiological changes occur, such as the cessation of female fertility and decreased sexual activity in men, or the transition from genital to non-genital. .

Menopause is an aging phenomenon, and although it comes to everyone, the timing of it varies from person to person, and the severity of symptoms varies from person to person. For women, menopause refers to the period from several years before menopause, when the abnormal menstrual cycle gradually begins to several years after menopause due to the decline in ovarian function. Many physical symptoms appear before and after menopause, which are called menopause symptoms. Menopause is a medical condition in which ovarian function declines, the production of hormones produced by the ovaries decreases, menstruation stops, and pregnancy is no longer possible.

At menopause, the ovarian function gradually declines and the secretion of estrogen decreases, but the secretion of gonadotropin, which is secreted by the pituitary gland to stimulate the ovaries, and enhances follicle development and ovulation function, increases. As estrogen decreases and the hormone suppression function acting on the center is not active, the gonadotropin increases, resulting in hormonal imbalance and various symptoms related to menopause.

When the balance is disturbed due to an abnormality in the hormonal central activity, it also affects the nearby autonomic nerve center, causing the autonomic nerve function to be misaligned and various symptoms appear. In particular, the autonomic nervous system is a nervous system that plays an important role in life such as breathing, circulation, excretion, body temperature, and hormone regulation as it is surrounded by the body. This instability leads to a state of 'autonomic ataxia'.

Among menopausal symptoms, hot flashes appear in 85% of postmenopausal women and are the most characteristic symptom. That is, redness appears on the skin of the head, neck, and chest along with a strong feeling of heat in the body cavity. These symptoms usually last from a few seconds to a few minutes and are more frequent at night or during stress. Most of them experience symptoms for more than 1 year, and it is known that 25-50% of cases persist for more than 5 years.

In addition, in menopause, symptoms such as cold sweat, fatigue, nervous sensitivity, headache, sleep disturbance (insomnia, early wake-up), insomnia, anxiety, apathy, depression, depression, muscle and joint pain, and dizziness may appear. Among these symptoms, depression and anxiety are the most frequent symptoms experienced by modern people and have the greatest impact on quality of life, and it is important to manage these symptoms well during menopause. In addition, it has been reported that the effect of estrogen on blood lipids, that is, there is a problem in the control of cholesterol content, resulting in thromboembolism and hypertension, and in severe cases, atherosclerotic cardiovascular disease. Therefore, as described above, cardiovascular management such as hot flashes, depression and anxiety, and cholesterol are very important for the early symptoms of menopause.

All women are bound to go through menopause. As the quality of life gradually improves, the desire to manage the symptoms that occur during menopause and to spend a healthy menopause is increasing. Hormone preparations commonly used in existing medicines have immediate effects but have many side effects, so interest in natural materials that can improve women's menopausal symptoms is increasing, and the need to study new physiological functions of various species is gradually increasing. have. In this regard, various previous studies are being conducted, but a lot of focus is on bone health, and development of materials that can simultaneously improve and manage hot flashes, depression and anxiety, and high cholesterol syndrome, which are essential for improving the quality of life in the early menopause, are yet to be developed. insufficient. It is necessary to continuously research and develop natural materials for improving women's menopausal symptoms that include ingredients that can be safely consumed by humans as active ingredients and can improve the quality of life during menopause.

It is an object of the present invention to provide a composition for treating, preventing and/or alleviating female menopausal symptoms, which can be safely administered to the human body, and containing two or more complex plant extracts, and a pharmaceutical and health functional food containing the composition would like to

According to one aspect, the present invention includes, as an active ingredient, at least two or more kinds of plant extracts from among complex plant extracts including motherwort ( Leonurus japonicas Houtt.) extract, Eclipta porstrata Linne extract, and Pueraria labata Ohwi extract. It provides a pharmaceutical composition for the treatment or prevention of female menopausal symptoms.

As an example, the plant extract may include the motherwort extract, the orchid extract, and the ginseng root extract.

In this case, the plant extract may include 20 to 40 parts by weight of the motherwort extract, 20 to 40 parts by weight of the orthrax extract, and 20 to 40 parts by weight of the orchid extract.

For example, the content of the plant extract in the pharmaceutical composition may be 10 μg/mL to 1000 μg/mL.

In another aspect, the present invention provides a drug for treating or preventing female menopausal symptoms comprising the above-described pharmaceutical composition.

In another aspect, the present invention includes, as an active ingredient, at least two or more kinds of plant extracts from a complex plant extract comprising motherwort ( Leonurus japonicas Houtt. ) extract, Eclipta porstrata Linne extract, and Pueraria labata Ohwi extract. It provides a food composition for alleviating female menopausal symptoms.

In another aspect, the present invention provides a health functional food for alleviating female menopausal symptoms comprising the above-described food composition.

According to the present invention, a complex plant extract in which at least two kinds of motherwort extract, chrysanthemum extract, and black root extract are combined treats, prevents or alleviates female menopausal symptoms. The active ingredient contained in the composition according to the present invention is derived from a plant, and safety is ensured because there is no side effect or toxicity even when administered to the human body.

A composition comprising the complex extract according to the present invention as an active ingredient treats, prevents, alleviates, and improves hot flashes, depression and anxiety, and high-cholesterol syndrome, which mainly occur in the menopausal period. The complex plant extract according to the present invention may be used as a pharmaceutical composition or drug for treating or preventing female menopausal symptoms and/or a food composition or health functional food for alleviating female menopausal symptoms.

1 is a graph showing the results of measuring cell proliferation ability in a cell line administered with one plant extract or a complex plant extract according to an exemplary embodiment of the present invention.
2 is a graph showing the results of measuring the cell proliferation ability in a cell line administered with a complex plant extract with different mixing ratios according to an exemplary embodiment of the present invention.
3A to 3B are graphs showing the results of measuring the expression levels of female hormone response genes Esr1, PGR, and pS2, respectively, compared to β-actin, in a cell line administered with a complex plant extract according to an exemplary embodiment of the present invention.
4 is a graph showing the results of measuring the tail temperature of a rat related to hot flashes after administration of a complex plant extract to rats for 4 weeks according to an exemplary embodiment of the present invention.
5 is a graph showing the results of measuring blood cholesterol levels related to high-cholesterol syndrome after administration of a complex plant extract to rats for 4 weeks according to an exemplary embodiment of the present invention.
6A and 6B show the results of administering a complex plant extract to rats for 12 weeks according to an exemplary embodiment of the present invention, and measuring the tail temperature of the rat at the 6th week of administration and the rectal temperature of the rat at the 12th week of administration, respectively. It is a graph.
7 is a graph showing the results of evaluation of behavioral experiments related to depression and anxiety after administration of a complex plant extract to rats for 12 weeks according to an exemplary embodiment of the present invention.
In the figure, Con or Vehicle is a negative control, Est is a positive control, Estradiol hormone, H is a motherwort extract, I is a motherwort extract, G is a brown root extract, Mix or HE is a motherwort extract, a motherwort extract, and a complex extract of chrysanthemum extract, respectively. Indicates the applied group. In addition, in the figure, Sham indicates a group in which the ovary of a rat used for the experiment was not dissected, but only an open operation, and OVX indicates a group in which the ovary of a rat was resected. In addition, compared to the negative control, statistically, if the p-value was less than 0.05, it was indicated by *, and if it was less than 0.01, it was indicated by **. The blending ratio shown in FIG. 2 represents the weight content of motherwort extract, orchid root extract, and black root extract.

Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings, if necessary.

[Composite plant extract and preparation method]

The composition for the treatment, prevention, alleviation and/or improvement of women's menopausal symptoms according to the present invention comprises a complex plant extract in which at least two kinds of plant extracts consisting of motherwort extract, nasturtium chrysanthemum extract and black root extract are blended as an active ingredient do.

Motherwort ( Leonurus japonicas Houtt.) refers to the medicinal herbs dried above the ground when the flowers of motherwort or motherwort, a biennial herb belonging to the family Lamiaceae, are in bloom. The indicator components of motherwort are known to be leonurine, stachydrine, leonuridine, rutin, and benzoic acid. In addition, it is said that it was named Mother Mother because it relieves all diseases of pregnancy and childbirth, and it is said that it is effective in controlling infertility and menstrual irregularities, so it is called the wife's good medicine (仙藥). In addition, it is said that it circulates the blood well, eliminates eohyeol, treats body swelling, and benefits urine.

Eclipta porstrata Linne (Eclipta porstrata Linne) is an annual herb in the Asteraceae family. The representative ingredients of orchid plant are known as ecliptin and wedelolactone. It is known that the representative effects of orchid plant include hemostasis, antibacterial effect, improvement of skin disease, and excellent effect on menstrual cramps. In particular, in oriental medicine prescriptions, it is used as a medicinal agent with efficacy in women's uterine inflammation, menstrual irregularity, menstrual pain, poor circulation, and insensitivity.

Pueraria lobata Ohwi refers to the dried root of arrowroot, a creeper belonging to the legume family, or the dried root after removing the bark. As representative components of galgeun, puerarin and daidzin, which are a kind of isoflavones, are known. The representative effect of galgeun is the mechanism of releasing heat while relaxing the muscles. It is also used to raise yang and stop diarrhea. It is also used to replenish the body's essence, quench thirst, and relieve alcohol poisoning.

According to the present invention, of these three plant extracts, at least two complex plant extracts are used. Each of these plant extracts can be obtained through the following method.

Each of the plant extracts according to the present invention may use a cold-chim extraction method, a warm-chim extraction method, or a heat extraction method, and a conventional extraction device, ultrasonic pulverization extractor, or fractionator may be used. As an example, when using an extraction solvent, a dried motherwort, chrysanthemum or ragweed sample is cut to an appropriate size, for example, 0.5 to 5 cm, cut and crushed to a powder state, put into an extraction container, and an appropriate extraction solvent is added to extract the extract. can be used to obtain

The extraction solvent for obtaining each of these plant extracts is water, 50% to 100% methanol, C ₁ to C ₅ alcohol such as ethanol, a polar solvent such as ethyl acetate, and an organic such as a non-polar solvent such as hexane, chloroform or dichloromethane a solvent or a mixed solvent thereof. Preferably, the extraction solvent may be hot water, 50% to 100% methanol, C ₁ to C ₅ alcohol such as ethanol, and more preferably 70% to 100% methanol or ethanol.

If necessary, the above process may be repeated several times or more to increase extraction efficiency. The extract may be filtered and concentrated under reduced pressure to prepare a crude extract for each plant sample. The obtained plant extract can be stored in a deep freezer until use. In addition, the plant extract may be one in which moisture is completely removed through concentration, freezing, and spray drying of the obtained extract, and the plant extract from which moisture is completely removed is used in powder form, or the powder is dissolved in distilled water or a common solvent. It can be melted and used.

If necessary, the plant extract obtained using an organic solvent or hot water may be fractionated using an additional solvent. Specifically, the plant extract obtained using hot water or an extraction solvent can be further subjected to a fractionation process with a solvent selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, and mixtures thereof. have. Preferably, the fractionation solvent may be an aqueous methanol solution, water, ethyl acetate, or chloroform.

The fraction obtained by performing the fractionation process may then be filtered or concentrated or dried to remove the solvent, and both filtration, concentration and drying may be performed. Specifically, the filtration may use filter paper or a reduced pressure filter, and the concentration may be concentrated under reduced pressure using a reduced pressure concentrator, for example, a rotary evaporator, and the drying may be performed by, for example, a freeze drying method. In an alternative embodiment, the plant extract obtained above may be fractionated using column chromatography. In another alternative embodiment, each fraction may be subjected to high performance liquid chromatography (HPLC) to purify a specific active ingredient.

In the present invention, the plant extract is a concept including all extracts, fractions, and purified products obtained in each step of extracting, fractionating or refining each plant raw material, and a dilution, concentrate or dried product thereof.

In one exemplary embodiment, the complex plant extract may consist of motherwort extract, nasturtium asiatica extract, and ginseng root extract. At this time, in the complex plant extract, motherwort extract, chrysanthemum extract, and black root extract may be each blended in a ratio of 20 to 40 parts by weight. The term parts by weight refers to the relative weight ratios of the components to be formulated herein unless otherwise indicated.

At menopause, the ovarian function gradually declines and the secretion of estrogen decreases, but the secretion of gonadotropin, which is secreted by the pituitary gland to stimulate the ovaries, and enhances follicle development and ovulation function, increases. As estrogen decreases, the hormone suppressing function acting on the central nervous system is not active, so the gonadotropin increases, resulting in hormonal imbalance and various symptoms related to menopause. The main symptoms of early menopause that appear due to the imbalance of female hormones are hot flashes, depression and anxiety, and problems with high-cholesterol syndrome. These symptoms are caused by a decrease in the concentration of estradiol among female hormones in the body.

With respect to the treatment, prevention, alleviation and/or improvement of female menopausal symptoms, the complex plant extract according to the present invention can play a role as an auxiliary hormone in vivo by promoting cell proliferation in a cell experiment using MCF-7 cells. There is (see Figures 1 and 2). In addition, it was confirmed that the expression of Esr1, PGR, and pS2 genes, which are genes related to female hormones, was improved in the corresponding cells (see FIGS. 3a, 3b and 3c).

In addition, it was confirmed that the selected complex plant extract treated, prevented, alleviated, and improved menopausal symptoms caused by ovarian resection in animal experiments using rats. It is known that, in the case of animals, the tail temperature rises in the early stages of ovariectomy, and the rectal temperature decreases later in the case of animals, just as hot flashes occur due to hormonal imbalance in the human body. In short-term animal experiments, the selected complex plant extract can homeostatically control the tail temperature, an indicator related to hot flashes, to a low level (see FIG. 4 ). In addition, the selected complex plant extract improved the high-cholesterol syndrome and was able to control the content of cholesterol in the blood to a low level (see FIG. 5 ).

In a long-term animal experiment, the selected complex plant extracts improved the hot flush-related index and homeostatically adjusted the tail temperature, a related index, to a low level from 3 to 6 weeks of administration, and from 7 to 12 weeks of administration, the related index, rectal. The temperature was constantly controlled to a high level. In addition, it is generally known that when depression induces, mobility decreases and immobility increases. The selected complex food extract was able to improve the depression and anxiety caused by ovariectomy by increasing the behavior and decreasing the immobility through the tail suspension experiment at 11 weeks of administration (see Figs. 6a, 6b, 7).

Based on these results, when at least two or more of the plant extracts of the three plant extracts according to the present invention are used in combination, hot flashes, depression and anxiety, and high-cholesterol syndrome are improved, thereby treating and preventing female menopausal symptoms. , it was confirmed that it can be used as an active ingredient, such as a composition for alleviating and/or improving.

[Composition, drug and health functional food]

Accordingly, the present invention relates to a composition for treating, preventing, alleviating and/or improving female menopausal symptoms, comprising the aforementioned complex plant extract as an active ingredient, and a pharmaceutical and/or health functional food comprising the composition. In one exemplary embodiment, the complex plant extract is administered in an amount of 1 μg/ml to 1000 μg/ml, preferably 10 μg/ml to 500 μg/ml in the composition for treating, preventing, alleviating and/or ameliorating female menopausal symptoms. It may be added at a concentration, but the present invention is not limited thereto.

In one aspect, the present invention relates to a pharmaceutical composition for treating or preventing female menopausal symptoms comprising the above-mentioned complex plant extract as an active ingredient, and a drug comprising the pharmaceutical composition.

The pharmaceutical composition or drug includes the complex plant extract according to the present invention as an active ingredient, and may further include a pharmaceutically acceptable carrier, excipient, diluent or accessory ingredient, if necessary.

The pharmaceutical composition or drug containing the complex plant extract according to the present invention as an active ingredient is prepared according to a conventional method for oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and the like. It may be formulated in the form of a sterile injectable solution and used. For example, the pharmaceutical composition and drug containing the complex plant extract of the present invention as an active ingredient may be administered in various oral or parenteral formulations during clinical administration, and when formulated, commonly used fillers, extenders, and binders , wetting agents, surfactants, anti-aggregating agents, lubricants, wetting agents, fragrances, emulsifiers or diluents such as emulsifiers or preservatives may further include diluents or excipients, and both oral and parenteral can be used.

For example, carriers, excipients and diluents that may be included in a pharmaceutical composition or drug containing the complex plant extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, Gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate , propylene glycol, liquid paraffin, and may be one or more selected from the group consisting of physiological saline, but is not limited thereto, and all conventional carriers, excipients or diluents may be used.

For example, solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the complex plant extract of the present invention, for example, starch, calcium carbonate (calcium carbonate), sucrose or lactose, gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweeteners, fragrances and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, glycerogelatin, and the like can be used. When administered parenterally, the drug for enhancing immunity of the present invention may be administered through subcutaneous injection, intravenous injection or intramuscular injection.

Forms for parenteral administration include toothpaste, mouthwash, topical administration agents (creams, ointments, dressing solutions, sprays, other coating agents, etc.). An example of the formulation of the topical administration agent may be one in which a complex plant extract as an active ingredient is impregnated into a carrier such as gauze made of natural or synthetic fibers. In the case of the above cream or ointment, it may be suitable for direct application to or around periodontal or gingival disease affected areas.

In the case of a spray, it can be prepared by a conventional spray preparation method, except that it contains a complex plant extract as an active ingredient, and it is filled and packaged in a compressed container or other spray container and sprayed frequently to the area of oral disease to enhance immune function. can be used to In the case of the dressing solution, it may be prepared by a conventional method for preparing a dressing solution, except for including the complex plant extract as an active ingredient.

In addition, the formulation of the pharmaceutical composition or drug according to the present invention may be in a desired form depending on the method of use, in particular a method known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal can be formulated by adopting Examples of specific formulations include warning agents, granules, lotions, liniments, limonades, powders, syrups, eye ointments, liquids, aerosols, EXTRACTS, elixils, ointments, fluid extracts, emulsions, suspensions, ointments, infusions, eye drops, tablets, suppositories, injections, spirits, capsules, creams, pills, soft or hard gelatin capsules, and the like.

Furthermore, the drug for improving female menopausal symptoms of the present invention uses an appropriate method known in the art or a method disclosed in Remington's Pharmaceutical Science (Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA). Thus, it can be preferably formulated.

If necessary, the pharmaceutical composition or drug according to the present invention may contain, in addition to the above active ingredients, nutrients, vitamins, electrolytes, flavoring agents, coloring agents, thickeners, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, It may further contain a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like.

The pharmaceutical composition or drug containing the complex plant extract of the present invention may be administered to mammals such as rats, mice, livestock, and humans by various routes. Any mode of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. In one exemplary embodiment, the complex plant extract as an active ingredient included in the pharmaceutical composition or drug in the present invention is 0.1 mg/kg to 1000 mg/kg, preferably 1 mg/kg to 500 mg/kg per day. can be administered to animals, but the present invention is not limited thereto.

In another aspect, the present invention relates to a food composition for alleviating and/or improving female menopausal symptoms comprising the above-mentioned complex plant extract as an active ingredient, and a health functional food comprising the food composition. In the present specification, food means a natural or processed product containing one or more nutrients, and includes all of food, food additives, health functional foods, beverages and beverage additives. Functional food is not particularly limited in components other than the complex plant extract, and may contain various flavoring agents or food supplement additives such as natural carbohydrates and/or suitable carriers, excipients and/or diluents commonly used in the manufacture of foods. can be used as

For example, foods containing the complex plant extract according to the present invention as an active ingredient include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, There are various soups, beverages, teas, drinks, alcoholic beverages, and vitamin complexes, and includes all health foods in the ordinary sense.

Examples of natural carbohydrates that can be used as food supplement additives include monosaccharides such as glucose and fructose; disaccharides such as maltose, sucrose and the like; Common sugars such as polysaccharides such as dextrin and cyclodextrin, as well as sugar alcohols such as xylitol, sorbitol, and erythritol. natural flavoring/sweetening agents such as taumatine, stevia extract (eg rebaudioside A, glycyrrhizin) as flavoring or sweetening agents other than those described above; Synthetic flavoring/sweetening agents such as saccharin and aspartame may be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the food composition or health functional food according to the present invention.

In addition, food compositions or health functional foods include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, carbonation agents used in alcoholic carbonated beverages, and the like. In addition, the functional food according to the present invention may contain natural fruit juice, fruit juice for the production of fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not so important, but is generally selected in the range of 0 to about 20 parts by weight, preferably 0.01 to 1.0 parts by weight, per 100 parts by weight of the complex plant extract according to the present invention.

Hereinafter, the present invention will be described through exemplary embodiments, but the present invention is not limited to the technical ideas described in the following examples.

Example 1: Preparation of plant extract

Plant extracts derived from motherwort, chrysanthemum, and chrysanthemum were prepared in the following way. Each plant raw material was dried and pulverized, and the raw material was hydrolyzed at a volume of 10 to 20 times the volume of the raw material so that the raw material could be sufficiently immersed, and extracted at 90 to 120 ° C. for 6 to 12 hours. The extract was separated into solid and liquid, and only the liquid was recovered, which was then dried and used as a sample. In the case of motherwort extract and orchid extract, after the primary extraction, it was again hydrolyzed to about 10 to 20 times the volume of the raw material, and extracted a second time at 90 to 120° C. for 3 to 6 hours. Compared with the case where only the primary extraction was performed through the secondary extraction, the yield was improved by about 1.5 times. An experiment was performed using motherwort (I), chrysanthemum plant (H), and brown root (G), and motherwort extract / chrysanthemum extract / garlic root extract were mixed in a predetermined weight ratio and used in the experiment.

Example 2: Measurement of cell proliferation

(1) Cell proliferation of single or complex plant extracts

To evaluate the cell proliferation ability of the plant extract, MCF-7 breast cancer cells were placed in a 24-well plate at a concentration of ^{5Х10 4 cells/well.} Each of the compound plant extracts in which the motherwort extract (H), motherwort extract (I), black root extract (G) and motherwort extract / orchid root extract / garlic root extract respectively prepared in Example 1 were formulated in a weight ratio of 34:33:33 were prepared, respectively. After treatment at a concentration of 50 μg/mL and culturing for 24 to 48 hours, the cell proliferation ability was measured using the WST-1 method. WST reagent was added to the cell culture medium and the absorbance was measured at 450 nm after reaction for 1 hour to evaluate the degree of cell proliferation. Estradiol hormone at the same concentration was used as a positive control. A measurement result according to this embodiment is shown in FIG. 1 . Compared with the case of using a single plant extract, it was confirmed that the cell proliferation ability was improved in the complex plant extract using three types of plant extracts in combination.

(2) Cell proliferation of complex plant extracts

The cell proliferation ability of the complex plant extract prepared in Example 1, prepared in the x-axis of motherwort extract, chrysanthemum extract, and chrysanthemum extract in the weight ratio specified on the x-axis of FIG. 2 was evaluated by repeating the procedure described in (1) above. The evaluation results according to the present embodiment are shown in FIG. 2 . Compared to the negative control, cell proliferation ability was improved even when two plant extracts were used in combination, and it was confirmed that the cell enhancing effect of the three plant extracts was further improved. Among the two plant extracts, the cell proliferation effect was the most excellent when the motherwort extract and the orchid extract were used in combination.

Example 3: Female hormone-related gene expression

In Example 2, to analyze the female hormone-related gene expression effect of the complex plant extract (Motherwort extract: Orchid root extract: Garlic root extract = 34:33:33 weight ratio) having the best cell proliferation effect, according to the administration of the complex plant extract The expression levels of Esr1, PGR, and pS2 genes, which are female hormone-related genes, were measured using PCR.

MCF-7 cells were placed ^{in a 6-well plate at a concentration of 5Х10 5} cells/well, and the complex plant extract was treated with 50 μg/mL. After culturing for 24 hours, RNA was extracted from the cells using the Trizol method, and cDNA was prepared at 30 °C for 10 minutes, 50 °C for 45 minutes, and 95 °C for 5 minutes. Esr1, pS2, and PGR genes of primers were added, and RT-PCR was performed to measure the expression level of each gene. For RT-PCR, cDNA, Primer, and pre-mix were mixed and maintained at 90° C. for 30 seconds, followed by repeating 40 cycles of min, 95° C. for 5 seconds, and 60° C. for 30 seconds. Primers used to amplify each gene were Taqman's Esr1 (Hs00174860_m1), PGR (Hs01556702_m1), pS2 (Hs00907239), and ACTB (Hs99999903).

The results of measuring the relative expression levels of female hormone-related genes according to the present embodiment are shown in FIGS. 3A to 3C, respectively. In the single plant extracts, motherwort extract promoted the expression of Esr1 gene, the orchids extract promoted the expression of pS2 gene, and the extracts of ginseng root stimulated the expression of the PGR gene. In particular, it was confirmed that the complex plant extract using three plant extracts further promoted the expression of these three female hormone-related genes compared to the single plant extract.

Example 4: Improvement of hot flashes and high-cholesterol syndrome through animal experiments

(1) Measurement of rat tail temperature

The dried sample was dissolved in distilled water and administered to rats (8-10 weeks old, SD rats, 40 rats) by oral administration. After acclimatization in the IVC facility of the laboratory animal room for about 1 week while freely supplying sterilized solid feed and water to the rats, 30 rats were randomly divided and subjected to ovarian resection (OVX), and 10 rats had only open laparotomy and no ovarian resection. Sham group. After a recovery period of 2 weeks, the ovariectomized group was randomly divided into 3 groups of 10 animals each, and various samples were orally administered daily together with the Sham group for 6 weeks. In the environment, temperature and humidity were kept constant, and the light and dark cycle was adjusted at intervals of 12 hours. A complex plant extract in which motherwort extract / chrysanthemum extract / ragweed extract in a weight ratio of 34:33:33 was orally administered daily at a dose of 100 mg/kg, the Sham group and the negative control group received distilled water, and the positive control group received Estradiol 3 μg/ kg each was orally administered. In relation to hot flashes, in order to measure the tail temperature of rats, it was measured twice a week using a thermometer for small animals in a subgroup at a distance of about 2 cm from the base of the tail of each group. The tail temperature measurement result is shown in FIG. It was confirmed that the complex plant extract using three plant extracts significantly lowered the tail temperature of rats in relation to hot flashes, thereby improving hot flash symptoms.

(2) analysis of blood markers in rats

Whole blood from the rat evaluated in (1) above was collected, left at room temperature for 30 minutes, and then centrifuged at 2000 x g, 4° C., for 15 minutes to separate serum. Serum was stored at -80°C, and total cholesterol content was measured as an indicator material related to high-cholesterol syndrome. The measurement result is shown in FIG. It was confirmed that the complex plant extract using three plant extracts significantly lowered the total cholesterol content that could be induced in menopausal symptoms.

Example 5: Improvement of hot flashes, depression and anxiety through long-term animal experiments

(1) Measurement of tail temperature and rectal temperature in hot flush-associated rats

The dried sample was dissolved in distilled water and orally administered to rats. 50 SD rats, 8-10 weeks old, were acclimatized in the IVC facility of the laboratory animal room for about a week while freely supplying sterilized solid feed and water. was assigned to the unresected Sham group. After a recovery period of 2 weeks, the ovariectomy group was randomly divided into 4 groups of 10 animals each, and various samples were orally administered daily together with the Sham group for 12 weeks. In the environment, temperature and humidity were kept constant, and the light and dark cycle was adjusted at intervals of 12 hours. Orally administered daily at 100 mg/kg for the low concentration group (HE_L) and 200 mg/kg for the high concentration group (HE_H) of a complex plant extract in which motherwort extract / chrysanthemum extract / garlic root extract combined in a weight ratio of 34:33:33 The Sham group and the negative control group were administered with distilled water, and the positive control group was administered with 3 μg/kg of Estradiol. The rat tail temperature was measured by repeating the same procedure as in Example 4. The rectal temperature of rats was measured by inserting the probe of an implantable thermometer for small animals into the anus twice a week by about 4 cm or more. The results of measurement of the tail temperature and rectal temperature of the rat are shown in FIGS. 6A and 6B . It was confirmed that the tail temperature and rectal temperature of the rats treated with the complex plant extract in which the three plant extracts were combined for a long time were significantly lowered.

(2) Depression and anxiety behavior analysis

Depression and anxiety are symptoms that increase in menopausal women, and in order to evaluate the improvement of the extract's symptoms of depression and anxiety, a tail suspension experiment was used to measure the helplessness of rats. At the 11th week of oral administration according to (1) above, the rat was acclimatized to the experimental environment for 1 hour, and then the rat's tail was wrapped around the tape to adjust the height so that one foot of the rat could touch the floor, and for 6 minutes While the rat's tail was hung, the number of times the rat's tail was suspended was measured. The measurement result is shown in FIG. Mobility was improved in rats that were orally administered with a complex plant extract using three plant extracts for a long period of time, and based on these results, it was confirmed that the complex plant extract improved depression and anxiety that may be caused during menopause in women.

In the above, the present invention has been described based on exemplary embodiments and examples of the present invention, but the present invention is not limited to the technical ideas described in the above embodiments and examples. Rather, those of ordinary skill in the art to which the present invention pertains can easily propose various modifications and changes based on the above-described embodiments and examples. However, it is clear from the appended claims that all such modifications and changes fall within the scope of the present invention.

Claims (10)

A plant extract including a motherwort ( Leonurus japonicas Houtt.) extract, an Eclipta porstrata Linne extract, and a Pueraria lobata Ohwi extract as an active ingredient, and 34% by weight of the motherwort extract, the motherwort extract in the plant extract, and the motherwort extract A pharmaceutical composition for treating or preventing female menopausal symptoms comprising 33% by weight and 33% by weight of the extract of ginseng root. The pharmaceutical composition for treating or preventing female menopausal symptoms according to claim 1, wherein the pharmaceutical composition further comprises any one of a pharmaceutically acceptable carrier, excipient, diluent, and accessory ingredient. delete The pharmaceutical composition for treating or preventing female menopausal symptoms according to claim 1, wherein the content of the plant extract in the pharmaceutical composition is 1 μg/ml to 1000 μg/ml. A drug comprising the pharmaceutical composition for treating or preventing female menopausal symptoms according to claim 1, 2 or 4. A plant extract including a motherwort ( Leonurus japonicas Houtt.) extract, an Eclipta porstrata Linne extract, and a Pueraria lobata Ohwi extract as an active ingredient, and 34% by weight of the motherwort extract, the motherwort extract in the plant extract, and the motherwort extract A food composition for alleviating symptoms of female menopause comprising 33% by weight and 33% by weight of the extract of ginseng root. The food composition of claim 6, wherein the food composition further comprises at least one of a food supplement additive component, a food engineering acceptable carrier, an excipient, and a diluent. delete According to claim 6, wherein the content of the plant extract in the food composition is 1 ㎍ / ㎖ to 1000 ㎍ / ㎖ food composition for alleviating female menopausal symptoms. A health functional food comprising the food composition for alleviating female menopausal symptoms according to claim 6, 7 or 9.

Images